Veterans Affairs, Department Of- Veterans Affairs, Department Of- Nac Pharmaceuticals ( 36e797) - Agency Bids & RFPs

The bid notice does not specify a delivery deadline for the products.

The bid notice does not specify payment terms.

The bid notice does not specify warranty information.

The bid notice states that the VA will award one contract to the responsible offeror who will be able to provide an uninterrupted source of supply for the contracted items.

The bid notice states that offers of covered drugs including biologics that fall within 21 CFR **** will only be considered for award if the offeror has an executed MA and PPA which includes the offered NDC's on file with the VA National Acquisition Center, FSS in accordance with 38 **** H 2. Furthermore, in order to be considered for award under this solicitation, all proposed covered drug product's must be present on the offeror's FSS contract or interim agreement with an established permanent FCP associated with the offeror's FSS contract or interim agreement by this solicitation's due date and time for receipt of offers. Offers failing to meet these criteria will be rejected and receive no further consideration. Proposed biosimilar products must be biological products licensed by the FDA under 42 U. S. C. 262 and must meet all biosimilar criteria described in 42 U. S. C. 262.

The bid notice does not specify penalties.

The bid notice does not mention a site visit.

The bid notice does not mention sample submission.

The bid notice does not specify a challenge deadline.

The bid notice does not provide an estimated total value for the procurement.

The bid notice states that the contract period will be for one year plus four pre-priced one year option periods. The tentative closing date for proposals is April 13, 2026. The notice does not specify a deadline for the total delivery of services beyond the contract period.

The bid notice states that the VA will award one contract to the responsible offeror who will be able to provide an uninterrupted source of supply for the contracted items.

The bid notice states that offers will be considered from all responsible sources.

The bid notice does not mention any requirement for a site visit.

The bid notice provides estimated annual usage for the items but does not state a total estimated monetary value for the contract.

The ordering period begins at the expiration of the implementation period, which is a maximum of 60 calendar days. The base year ordering period will be in effect for one year. The contract duration includes the implementation period plus one year ordering period with four one-year prepriced option ordering periods. The contractor shall not be required to make any deliveries under this contract after 15 calendar days from the expiration date of the contract.

The bid notice states that contractors will be receiving payments from the prime vendor programs instead of directly from the government. Invoices are to be submitted in accordance with the business-to-business agreements reached with the prime vendors. The government is not a party to these agreements and does not negotiate for either the contractor or prime vendors.

The bid notice states that the contractor warrants and implies that the items delivered under this contract are merchantable and fit for use for the particular purpose described in this contract.

The bid notice states that a contract will be awarded to the responsible offeror that submits an offer meeting the solicitation requirements, and is the lowest price technically acceptable offer.

To be considered for award, offerors must submit a price for the base year and all four one-year options for all line items. Offerors must list an 11-digit NDC number for each offered drug that is unique to the offeror's company. If the offeror is a distributor, the NDC number must be unique to the distributor. All offered pharmaceuticals must be FDA approved and verifiable by the contracting officer. All places of performance must be FDA CGMP acceptable for the product type offered and verifiable by the contracting officer. The manufacturing facility must have clearance by the FDA to manufacture under the specific NDA/ANDA cited used in the offer, and these FDA clearances must be verifiable by the contracting officer.

The bid notice mentions that failure to provide awarded product meeting all solicitation/contract requirements by the ordering period start date may result in contract termination in accordance with FAR ****(m), Termination for Cause. It also states that willful failure or refusal to furnish the required reports, or falsification thereof, shall constitute sufficient cause for terminating the contract.